Ferrer Freeman & Co

Ferrer Freeman & Co

Carlos Ferrer and David Freeman founded Ferrer Freeman & Co in 1995 after careers at GE Capital's equity unit. The firm set up in Greenwich, Connecticut with a deliberate mandate: invest only in healthcare. That constraint was unusual for the mid-1990s, when most middle-market private equity firms ran generalist portfolios. The founders structured the firm as a partnership that would concentrate capital, operational energy, and sector relationships into one vertical. FFC pursues growth equity and buyout investments in commercial-stage healthcare companies across three sub-sectors: healthcare services, medical devices, and specialty pharmaceuticals. The firm typically writes equity checks of $15 million to $50 million per deal, targeting companies with $5 million to $50 million in revenue. Portfolio positions have historically included companies in outsourced pharmaceutical services, ambulatory surgery centers, specialty physician practice management, and diagnostic imaging. The firm exited several portfolio companies through strategic sales to larger healthcare consolidators, a pattern consistent with its focus on building platforms attractive to strategic acquirers. FFC closed its fourth fund, Ferrer Freeman & Co IV, in 2006, at roughly the same scale as prior vehicles. The firm continued managing its portfolio through the late 2000s and 2010s, largely harvesting existing investments rather than deploying fresh capital. In September 2013, the firm realized a significant exit when portfolio company Medpace, a clinical research organization, completed its initial public offering on the Nasdaq — a transaction that marked the maturation of an investment held for nearly a decade. FFC illustrates a mid-market private equity model that bet entirely on sector specialization before it became standard industry practice. Unlike generalist firms that later added healthcare-dedicated teams, FFC was born into the constraint. The firm's partnership structure survived the departure of founding capital sources and the structural shift from GE-linked origins to independent institutional fundraising. Its post-deployment posture — managing legacy assets without successive fundraises — matches a pattern of founder-led firms that wind down investment activity but maintain fiduciary responsibility for remaining portfolio companies.